healthy healthy
Conditions
Interventions
Take the 3 drugs, respectively, then 60 minutes PET scan using [18F] FE-PE2I and 60 minutes fMRI scan from the time when the maximum blood concentration is reached after taking the drugs.
1. dl-methyl
Sponsors
Tateno Amane
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Subjects who are 20 years old or older and younger than 40 years old when obtaining consents 2) Subjects with no history of psychiatric and/or neurological disorders 3) Subjects with normal BMI (18.5-25) 4) Subjects without the history of smoking 5) Subjects who have the ability to provide informed consent and adhere to the protocol.
Exclusion criteria
Exclusion criteria: 1) Subjects who are contraindicated for dl-methylephedrine or pseudoephedrine. a) taking cathecholamines b) with a history of hypersensitivity to dellegra or compouds similar in chemical structure to pseudoephedrine (ephedrine or methylephedrine) c) with severe hypertension d) with severe coronary aretery disease e) with angle-closure glaucoma f) with urinary retention g) with a hisotry of insomnia, dizziness, weakness, tremor, arrhythmia due to sympathomimetics 2) Subjects who are subject to careful administration of dl-methylephedrine or pseudoephedrine. a) with hyperthyroidism b) with hypertension c) with heart disease d) with diabetes mellitus e) with elevated intraocular pressure f) with prostatic hypertrophy g) with renal dysfunction 3) Subjects who have gastrointenstinal symptoms when taking lactose 4) Subjcts who received drug therapy within 1 week before obtaining consent 5) Subjects who are contraindicated for the use of MRI 6) Subjects who took cafein (by 2 days before the test) or alcohol (by the day before the test). 7) Subjects who has been exposed to radiation by job-related exposuer or therapy in one year exceeding 15mSv. 8) Subjects who have received contrast agents (X-ray, MRI) or radiopharmaceuticals within 2 days of the examination, or plan to do the day after the examination. 9) Athletes at the competition level 10) Subjects who do not agree to notify the results of the examination which requires treatment 11) Subjects who are judged as not suitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the change of binding potential of dopamine transporter (in striatum, nucleus accumbens, thalamus, substantia nigra) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. the change of BOLD signal 2. Correct answer rate and reaction time of cognitive tasks during fMRI 3. blood and urine concentration of dl-methylephedrine and pseudoephedrine, urine concentration o cafeine 4. evaluation of higher brain function by neuropsychological test 5. evaluation of subjective mood by psychological test | — |
Contacts
Public ContactAmane Tateno
Department of Neuropsychiatry, Nippon Medical School
Outcome results
None listed